Table 1.
The baseline of the patients included in the dataset.
| Train and validation | Test | Total | |
|---|---|---|---|
| (n = 241) | (n = 50) | (n = 291) | |
| Pathologic stage | |||
| AIS | 47 (19.50%) | 14 (28.00%) | 61 (20.96%) |
| MIA | 69 (28.63%) | 11 (22.00%) | 80 (27.49%) |
| IA | 97 (40.25%) | 20 (40.00%) | 117 (40.21%) |
| MPs | 28 (11.62%) | 5 (10.00%) | 33 (11.34%) |
| Age (y) (mean ± std) | 56.52 ± 10.29 | 58.04 ± 11.80 | 56.78 ± 10.56 |
| Sex | |||
| Male | 98 (40.66%) | 17 (34.00%) | 115 (39.52%) |
| Female | 143 (59.34%) | 33 (66.00%) | 176 (60.48%) |
| Nodule size | |||
| (0–1.0 cm] | 86 (35.68%) | 18 (36.00%) | 104 (35.74%) |
| (1.0–2.0 cm] | 124 (51.45%) | 26 (52.00%) | 150 (51.55%) |
| (2.0–3.0 cm] | 31 (12.86%) | 6 (12.00%) | 37 (12.71%) |
| Nodule location | |||
| RU | 90 (37.34%) | 17 (34.00%) | 107 (36.77%) |
| RM | 22 (9.13%) | 2 (4.00%) | 24 (8.25%) |
| RD | 38 (15.77%) | 9 (18.00%) | 47 (16.15%) |
| LU | 62 (25.73%) | 11 (22.00%) | 73 (25.09%) |
| LD | 29 (12.03%) | 11 (22.00%) | 40 (13.75%) |
AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; IA, invasive adenocarcinoma; MPs, invasive adenocarcinoma with micropapilary components; RU, the right-up lobe; RM, the right-middle lobe; RD, the right-down lobe; LU, the left-up lobe; LD, the left-down lobe.